{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRI+Study&page=41", "query": { "intervention": "MRI Study", "page": 41 }, "page_size": 10 }, "pagination": { "page": 41, "page_size": 10, "total_count": 3282, "total_pages": 329, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRI+Study&page=42&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRI+Study&page=40&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T12:47:35.954Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05432791", "title": "Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Locally Advanced Uterine Corpus Leiomyosarcoma", "Metastatic Uterine Corpus Leiomyosarcoma", "Stage III Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8", "Unresectable Uterine Corpus Leiomyosarcoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Trabectedin", "type": "DRUG" }, { "name": "Transthoracic Echocardiography Test", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2023-03-30", "completion_date": "2027-01-30", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-27T12:47:35.954Z", "location_count": 144, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 120 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Dublin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05432791" }, { "nct_id": "NCT04576117", "title": "A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Low Grade Astrocytoma", "Recurrent WHO Grade 2 Glioma", "Refractory Low Grade Astrocytoma", "Refractory Low Grade Glioma", "Refractory WHO Grade 1 Glioma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Vinblastine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 300, "start_date": "2021-02-16", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-27T12:47:35.954Z", "location_count": 91, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 77 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04576117" }, { "nct_id": "NCT06860815", "title": "Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Metastatic Carcinoma in the Liver" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Transarterial Radioembolization", "type": "RADIATION" }, { "name": "Yttrium Y 90 Resin Microspheres", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2026-01-30", "completion_date": "2027-01-30", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-27T12:47:35.954Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06860815" }, { "nct_id": "NCT04583774", "title": "Developing an EEG Paradigm to Study Prediction Error in Anorexia Nervosa", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anorexia Nervosa" ], "interventions": [ { "name": "Prediction error tasks", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": "17 Years", "sex": "FEMALE", "summary": "11 Years to 17 Years · Female only" }, "enrollment_count": 47, "start_date": "2021-02-09", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-27T12:47:35.954Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04583774" }, { "nct_id": "NCT06169124", "title": "Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Ovarian Granulosa Cell Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 17, "start_date": "2024-02-08", "completion_date": "2027-07-24", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-27T12:47:35.954Z", "location_count": 66, "location_summary": "Los Angeles, California • Newark, Delaware • Boise, Idaho + 55 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Boise", "state": "Idaho" }, { "city": "Caldwell", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT06169124" }, { "nct_id": "NCT05672251", "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia", "Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Loncastuximab Tesirine", "type": "BIOLOGICAL" }, { "name": "Mosunetuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2024-01-02", "completion_date": "2029-08-24", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-27T12:47:35.954Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05672251" }, { "nct_id": "NCT05388877", "title": "E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Neoplasm in the Central Nervous System", "Metastatic Melanoma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "MEK-1/MEKK-1 Inhibitor E6201", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2022-10-20", "completion_date": "2025-06-02", "has_results": false, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-10-27T12:47:35.954Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05388877" }, { "nct_id": "NCT06580054", "title": "Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck", "Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck", "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Digital Photography", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2025-03-05", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-27T12:47:35.954Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06580054" }, { "nct_id": "NCT06315595", "title": "Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Neoplasm" ], "interventions": [ { "name": "Non-Interventional Study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2015-09-30", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-27T12:47:35.954Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06315595" }, { "nct_id": "NCT06918132", "title": "Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Fianlimab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-05-02", "completion_date": "2033-12-02", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-27T12:47:35.954Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06918132" } ] }